Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.
Yong-Pyo LeeSung Yong OhKwang Min KimSe-Il GoSeung Tae KimSeok Jae HuhJung Hun KangJun Ho JiPublished in: Cancers (2022)
The efficacy of mFOLFIRINOX as a second-line treatment in advanced BTC patients after the failure of gemcitabine-based first-line treatment was replicated, albeit with slightly shorter survival results compared to previous studies. Long-term administration of mFOLFIRINOX with toxicity management might offer a survival benefit.
Keyphrases
- phase ii study
- locally advanced
- end stage renal disease
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- open label
- peritoneal dialysis
- radiation therapy
- clinical trial
- papillary thyroid
- patient reported outcomes
- free survival
- lymph node metastasis
- study protocol
- smoking cessation
- replacement therapy
- patient reported
- childhood cancer